4.6 Article

Human but Not Mouse Hepatocytes Respond to Interferon-Lambda In Vivo

期刊

PLOS ONE
卷 9, 期 1, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0087906

关键词

-

资金

  1. National Fund for Scientific Research (FNRS-FRSM)
  2. Research Foundation Flanders (FWO) [3G052112]
  3. Ghent University (GOA) [01G01712]
  4. Action de Recherche Concertee (ARC) of the French Community of Belgium
  5. Interuniversitary Attraction Poles programme
  6. Belgian Science Policy Office [PAI-P7/45 BELVIR, IAP-P7/47-HEPRO2]
  7. Excellence Initiative of the German Research Foundation (GSC-4, Spemann Graduate School)

向作者/读者索取更多资源

The type III interferon (IFN) receptor is preferentially expressed by epithelial cells. It is made of two subunits: IFNLR1, which is specific to IFN-lambda (IFN-lambda) and IL10RB, which is shared by other cytokine receptors. Human hepatocytes express IFNLR1 and respond to IFN-lambda. In contrast, the IFN-lambda response of the mouse liver is very weak and IFNLR1 expression is hardly detectable in this organ. Here we investigated the IFN-lambda response at the cellular level in the mouse liver and we tested whether human and mouse hepatocytes truly differ in responsiveness to IFN-lambda. When monitoring expression of the IFN-responsive Mx genes by immunohistofluorescence, we observed that the IFN-lambda response in mouse livers was restricted to cholangiocytes, which form the bile ducts, and that mouse hepatocytes were indeed not responsive to IFN-lambda. The lack of mouse hepatocyte response to IFN-lambda was observed in different experimental settings, including the infection with a hepatotropic strain of influenza A virus which triggered a strong local production of IFN-lambda. With the help of chimeric mice containing transplanted human hepatocytes, we show that hepatocytes of human origin readily responded to IFN-lambda in a murine environment. Thus, our data suggest that human but not mouse hepatocytes are responsive to IFN-lambda in vivo. The non-responsiveness is an intrinsic property of mouse hepatocytes and is not due to the mouse liver micro-environment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Multidisciplinary Sciences

PKR activity modulation by phosphomimetic mutations of serine residues located three aminoacids upstream of double-stranded RNA binding motifs

Teresa Cesaro, Yohei Hayashi, Fabian Borghese, Didier Vertommen, Fanny Wavreil, Thomas Michiels

Summary: PKR, known for its role in viral infection response and cellular homeostasis, was found to have novel phosphorylation sites at Ser6 and Ser97 in this study. Modulating the phosphorylation status at these sites can regulate PKR activity.

SCIENTIFIC REPORTS (2021)

Review Virology

Nucleocytoplasmic Trafficking Perturbation Induced by Picornaviruses

Belen Lizcano-Perret, Thomas Michiels

Summary: Picornaviruses disrupt host nucleocytoplasmic trafficking by targeting FG-nucleoporins in the nuclear pore complex, leading to increased viral genome translation and replication. This interference affects innate immune responses and ribosomal machinery availability, facilitating viral RNA translation.

VIRUSES-BASEL (2021)

Article Multidisciplinary Sciences

A case of convergent evolution: Several viral and bacterial pathogens hijack RSK kinases through a common linear motif

Frederic Sorgeloos, Michael Peeters, Yohei Hayashi, Fabian Borghese, Nicolas Capelli, Melissa Drappier, Teresa Cesaro, Didier Colau, Vincent Stroobant, Didier Vertommen, Gregory de Bodt, Stephane Messe, Ignasi Forne, Felix Mueller-Planitz, Jean-Francois Collet, Thomas Michiels

Summary: Microbes have evolved to exploit cellular kinases called RSKs, which play a role in defending against pathogens. Kaposi's sarcoma-associated herpesvirus and Yersinia use a similar strategy to manipulate RSKs.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)

Article Multidisciplinary Sciences

Development of SARS-CoV2 humoral response including neutralizing antibodies is not sufficient to protect patients against fatal infection

Mathilde Choteau, Anais Scohy, Stephane Messe, Mathieu Luyckx, Melanie Dechamps, Virginie Montiel, Jean Cyr Yombi, Damien Gruson, Nisha Limaye, Thomas Michiels, Laure Dumoutier

Summary: More than a year into the pandemic, COVID-19 continues to be a global health emergency. The role of antibodies in viral clearance and disease severity remains controversial. Patients with severe COVID-19, including those who died, have higher levels of virus-specific antibodies, indicating that fatal infection is not associated with a deficient humoral response. Most recovered patients still have antibodies against SARS-CoV-2 more than 3 months after infection.

SCIENTIFIC REPORTS (2022)

Article Immunology

A Role for B Cells to Transmit Hepatitis C Virus Infection

Isabelle Desombere, Freya Van Houtte, Ali Farhoudi, Lieven Verhoye, Caroline Buysschaert, Yvonne Gijbels, Sibyl Couvent, Wilfried Swinnen, Hans Van Vlierberghe, Andre Elewaut, Andrea Magri, Zania Stamataki, Philip Meuleman, Jane A. McKeating, Geert Leroux-Roels

Summary: Hepatitis C virus can be transmitted by B cells, but B cells from recently infected patients failed to transmit the virus to mice, while all serum samples were infectious. The study also observed an association between circulating antibodies and B cell transmission of HCV.

FRONTIERS IN IMMUNOLOGY (2021)

Article Microbiology

Study of Hepatitis E Virus-4 Infection in Human Liver-Chimeric, Immunodeficient, and Immunocompetent Mice

Laura Collignon, Lieven Verhoye, Renate Hakze-Van der Honing, Wim H. M. Van der Poel, Philip Meuleman

Summary: The hepatitis E virus (HEV) causes 20 million infections annually worldwide, with immunocompromised individuals at risk of developing chronic infections. Human liver-chimeric mice have been instrumental in HEV research, but only two genotypes have been studied in this model. Recent studies show susceptibility of nude Balb/c mice to a HEV-4 strain.

FRONTIERS IN MICROBIOLOGY (2022)

Article Cell Biology

Viral Interference of Hepatitis C and E Virus Replication in Novel Experimental Co-Infection Systems

Thomas Burkard, Nora Proske, Kathrin Resner, Laura Collignon, Leonard Knegendorf, Martina Friesland, Lieven Verhoye, Ibrahim M. Sayed, Yannick Bruggemann, Maximilian K. Nocke, Patrick Behrendt, Heiner Wedemeyer, Philip Meuleman, Daniel Todt, Eike Steinmann

Summary: This study found direct interference between HCV and HEV in human hepatocytes and humanized mice. The protease activity of HCV was found to be linked to this interference. In vivo experiments confirmed that super-infection reduced the replication of both viruses in individual mice.
Article Microbiology

A Hepatitis C virus genotype 1b post-transplant isolate with high replication efficiency in cell culture and its adaptation to infectious virus production in vitro and in vivo

Christian Heuss, Paul Rothhaar, Rani Burm, Ji-Young Lee, Philipp Ralfs, Uta Haselmann, Luisa J. Stroh, Ombretta Colasanti, Cong Si Tran, Noemi Schafer, Paul Schnitzler, Uta Merle, Ralf Bartenschlager, Arvind H. Patel, Frederik Graw, Thomas Krey, Vibor Laketa, Philip Meuleman, Volker Lohmann

Summary: This study reports an efficient infectious cell culture model for hepatitis C virus (HCV), which can be used for studying infection mechanisms and developing vaccines. The model, generated from a consensus gt1b genome, underwent long-term passaging to adapt and produce high levels of transmissible infectivity. The study's findings are important for understanding the transmission mechanisms of HCV and for research and prevention of HCV.

PLOS PATHOGENS (2022)

Article Gastroenterology & Hepatology

Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections

Rani Burm, Panagiota Maravelia, Gustaf Ahlen, Sandra Ciesek, Noelia Caro Perez, Anna Pasetto, Stephan Urban, Freya Van Houtte, Lieven Verhoye, Heiner Wedemeyer, Magnus Johansson, Lars Frelin, Matti Sallberg, Philip Meuleman

Summary: This study demonstrates the immunogenicity and effectiveness of preS1-HDAg immunotherapy in preventing HBV and HDV infections both in vitro and in vivo. The vaccine can complement current and future therapies for the control of chronic HBV and HDV infection.
Article Gastroenterology & Hepatology

Adeno-associated virus serotype 2 capsid variants for improved liver-directed gene therapy

Nadja Meumann, Marti Cabanes-Creus, Moritz Ertelt, Renina Gale Navarro, Julie Lucifora, Qinggong Yuan, Karin Nien-Huber, Ahmed Abdelrahman, Xuan-Khang Vu, Liang Zhang, Ann-Christin Franke, Christian Schmithals, Albrecht Piiper, Annabelle Vogt, Maria Gonzalez-Carmona, Jochen T. Frueh, Evelyn Ullrich, Philip Meuleman, Steven R. Talbot, Margarete Odenthal, Michael Ott, Erhard Seifried, Clara T. Schoeder, Joachim Schwable, Leszek Lisowski, Hildegard Buning

Summary: This article reports two gene vector variants, MLIV.K and MLIV.A, which were obtained through in vivo AAV peptide display selection in mice. They showed improved hepatocyte targeting and transduction efficiency compared to AAV2 and AAV8, and have potential for liver disease treatment.

HEPATOLOGY (2023)

Article Cell Biology

Human hepatocyte PNPLA3-148M exacerbates rapid non-alcoholic fatty liver disease development in chimeric mice

Mohammad Kabbani, Eleftherios Michailidis, Sandra Steensels, Clifton G. Fulmer, Joseph M. Luna, Jeremie Le Pen, Matteo Tardelli, Brandon Razooky, Inna Ricardo-Lax, Chenhui Zou, Briana Zeck, Ansgar F. Stenzel, Corrine Quirk, Lander Foquet, Alison W. Ashbrook, William M. Schneider, Serkan Belkaya, Gadi Lalazar, Yupu Liang, Meredith Pittman, Lindsey Devisscher, Hirosh Suemizu, Neil D. Theise, Luis Chiriboga, David E. Cohen, Robert Copenhaver, Markus Grompe, Philip Meuleman, Baran A. Ersoy, Charles M. Rice, Ype P. de Jong

Summary: Research shows that PNPLA3-148M variant in human hepatocytes exacerbates advanced non-alcoholic fatty liver disease (NAFLD). These models will aid in understanding the contribution of human genetic variants to advanced fatty liver diseases.

CELL REPORTS (2022)

Article Microbiology

Cardiovirus leader proteins retarget RSK kinases toward alternative substrates to perturb nucleocytoplasmic traffic

Belen Lizcano-Perret, Cecile Lardinois, Fanny Wavreil, Philippe Hauchamps, Gaetan Herinckx, Frederic Sorgeloos, Didier Vertommen, Laurent Gatto, Thomas Michiels

Summary: It has been discovered that certain pathogen proteins can hijack cellular protein kinases to promote their own replication or evade immunity by redirecting them to specific substrates.

PLOS PATHOGENS (2022)

Article Gastroenterology & Hepatology

A human monoclonal antibody against HBsAg for the prevention and treatment of chronic HBV and HDV infection

Rani Burm, Freya Van Houtte, Lieven Verhoye, Ahmed Atef Mesalam, Sandra Ciesek, Philippe Roingeard, Heiner Wedemeyer, Geert Leroux-Roels, Philip Meuleman

Summary: This study evaluated a specific antibody against HBV/HDV infection and found that it could prevent infection and reduce viral loads, providing a valuable candidate for the functional cure of chronic HBV and HDV infections.

JHEP REPORTS (2023)

Meeting Abstract Gastroenterology & Hepatology

IMMUNOTHERAPY AGAINST HBV AND HDV THAT BYPASSES IMMUNOLOGICAL DYSFUNCTION.

Lars Frelin, Panagiota Maravelia, Rani Burm, Gustaf Ahlen, Lieven Verhoye, Freya Van Houtte, Philip Meuleman, Matti Sallberg

HEPATOLOGY (2022)

Meeting Abstract Gastroenterology & Hepatology

Heterologous prime-boost immunotherapy circumvents tolerance and induces broadly neutralizing antibodies that protects against hepatitis B and D co-infection and hepatitis D super-infection

Lars Frelin, Panagiota Maravelia, Rani Burm, Yi Ni, Gustaf Ahlen, Lieven Verhoye, Freya Van Houtte, Anna Pasetto, Stephan Urban, Philip Meuleman, Matti Saellberg

JOURNAL OF HEPATOLOGY (2022)

暂无数据